Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
Top Cited Papers
Open Access
- 19 November 2010
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 376 (9753), 1670-1681
- https://doi.org/10.1016/s0140-6736(10)61350-5
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trialThe Lancet, 2010
- Rosuvastatin and Cardiovascular Events in Patients Undergoing HemodialysisThe New England Journal of Medicine, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinThe New England Journal of Medicine, 2008
- Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Low LDL-C Levels and Cancer: Reassuring But Still Not DefinitiveJournal of the American College of Cardiology, 2008
- Rosuvastatin in Older Patients with Systolic Heart FailureThe New England Journal of Medicine, 2007
- Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)JAMA, 2002
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsThe New England Journal of Medicine, 1998
- Benefits and Risks of HMG-CoA Reductase Inhibitors in the Prevention of Coronary Heart Disease A ReappraisalDrug Safety, 1996
- Serum Cholesterol Levels and Six-Year Mortality from Stroke in 350,977 Men Screened for the Multiple Risk Factor Intervention TrialThe New England Journal of Medicine, 1989